INTERNATIONAL JOURNAL OF HEMATOLOGY

Scope & Guideline

Unveiling Innovations in Hematology

Introduction

Welcome to your portal for understanding INTERNATIONAL JOURNAL OF HEMATOLOGY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0925-5710
PublisherSPRINGER JAPAN KK
Support Open AccessNo
CountryJapan
TypeJournal
Convergefrom 1991 to 2024
AbbreviationINT J HEMATOL / Int. J. Hematol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO 105-6005, JAPAN

Aims and Scopes

The International Journal of Hematology focuses on advancing the field of hematology through rigorous research and clinical studies. The journal encompasses a wide array of topics related to blood disorders, treatments, and innovative methodologies that enhance our understanding of hematological conditions.
  1. Hematological Malignancies:
    The journal extensively covers research on hematological malignancies such as leukemia, lymphoma, and myeloma, focusing on their pathophysiology, diagnosis, and treatment strategies.
  2. Bone Marrow and Stem Cell Transplantation:
    A significant portion of the research is dedicated to the methodologies and outcomes of bone marrow and stem cell transplantation, including allogeneic and autologous transplants.
  3. Coagulation Disorders:
    The journal addresses various coagulation disorders, including hemophilia and thrombocytopenia, examining both the clinical implications and therapeutic approaches.
  4. Transfusion Medicine:
    Research related to blood transfusion practices, including safety and efficacy, is a core area of focus, highlighting advancements in transfusion strategies.
  5. Genetic and Molecular Pathology:
    There is a significant emphasis on the genetic and molecular aspects of hematological diseases, including studies on mutations, gene expression, and their implications for treatment.
  6. Innovative Therapies and Clinical Trials:
    The journal highlights the latest innovations in therapy, including novel drug therapies, immunotherapies, and clinical trial outcomes that impact patient care.
  7. Patient Outcomes and Quality of Life:
    Research evaluating patient outcomes, quality of life, and psychosocial aspects of living with hematological disorders is increasingly featured, emphasizing holistic care.
The International Journal of Hematology has identified several trending and emerging themes that reflect the current advancements and interests in the field of hematology. These trends highlight the evolving nature of research priorities and the integration of innovative approaches to treatment.
  1. Precision Medicine:
    There is a marked increase in research focusing on precision medicine approaches in hematology, tailoring treatments based on genetic and molecular profiling of patients.
  2. Immunotherapy Developments:
    Studies on immunotherapy, particularly CAR-T cell therapies and bispecific antibodies, are trending, reflecting a significant shift towards utilizing the immune system to combat hematological malignancies.
  3. Real-World Evidence and Outcomes Research:
    Research that provides real-world evidence on treatment effectiveness and patient outcomes is gaining traction, emphasizing the need for practical insights beyond clinical trial settings.
  4. Molecular and Genetic Insights:
    Emerging themes include detailed molecular and genetic analyses of hematological disorders, contributing to better understanding of disease mechanisms and targeted therapies.
  5. Management of COVID-19 in Hematology Patients:
    Given the global pandemic, there is a growing interest in understanding the implications of COVID-19 on patients with hematological conditions, including treatment adaptations and outcomes.
  6. Patient-Centric Care and Quality of Life:
    Research focusing on patient-reported outcomes and quality of life measures is increasingly emphasized, reflecting a broader understanding of patient experiences and needs.

Declining or Waning

While the International Journal of Hematology has a robust focus on several key areas, some themes have shown a decline in prominence over recent years. This can indicate shifts in research interest or advancements in treatment that may render previous topics less critical.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decrease in publications focused solely on traditional chemotherapy regimens, as the field increasingly shifts towards targeted therapies and personalized medicine.
  2. Basic Hematology Research:
    Basic research in hematology, particularly studies that do not translate into clinical applications, appears to be waning as the emphasis moves towards translational and clinical research.
  3. Longitudinal Studies of Established Treatments:
    Longitudinal studies examining established treatment regimens without new intervention strategies have become less frequent, possibly due to a focus on novel therapies.
  4. Epidemiological Studies:
    The publication of epidemiological studies related to hematological conditions has declined, potentially reflecting a shift towards more clinical and therapeutic research.
  5. Animal Models in Hematology Research:
    Research utilizing animal models for hematological studies is less frequently published, as there is a growing preference for human-centric clinical research.

Similar Journals

AMERICAN JOURNAL OF HEMATOLOGY

Elevating Knowledge in Blood Health and Treatment
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

Hematologie

Unveiling New Insights in Hematological Research
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1264-7527Frequency: 6 issues/year

Hematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.

HAEMATOLOGICA

Exploring the Depths of Blood Science: A Legacy Since 1947
Publisher: FERRATA STORTI FOUNDATIONISSN: 0390-6078Frequency: 12 issues/year

HAEMATOLOGICA, published by FERRATA STORTI FOUNDATION, is a prestigious journal in the field of hematology, recognized for its high impact and contribution to advancing research in this critical area of medicine. With an impressive Q1 ranking in the 2023 category of Hematology and a notable Scopus rank of #12 out of 137, the journal serves as an essential platform for disseminating innovative studies, clinical trials, and comprehensive reviews from 1947 to 2024. Based in Italy, with a commitment to quality and academic integrity, HAEMATOLOGICA fosters collaboration among researchers, practitioners, and students interested in the latest developments and methodologies within hematological science. Although it does not offer open access, the journal ensures that valuable insights are accessible through institutional subscriptions, emphasizing its role in shaping the future of hematologic research.

PEDIATRIC HEMATOLOGY AND ONCOLOGY

Uniting researchers and practitioners for a healthier future.
Publisher: TAYLOR & FRANCIS INCISSN: 0888-0018Frequency: 8 issues/year

Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.

CURRENT OPINION IN HEMATOLOGY

Empowering clinicians and researchers with cutting-edge insights.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

BONE MARROW TRANSPLANTATION

Leading the Charge in Cutting-edge Transplantation Research.
Publisher: SPRINGERNATUREISSN: 0268-3369Frequency: 12 issues/year

BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.

BRITISH JOURNAL OF HAEMATOLOGY

Exploring Innovations in Blood Health and Disease
Publisher: WILEYISSN: 0007-1048Frequency: 23 issues/year

British Journal of Haematology, published by Wiley, is a leading journal in the field of hematology, with an impressive impact factor reflecting its significance in the medical research community. Established in 1955, the journal has consistently contributed to advancing knowledge in hematology, currently holding a prestigious Q1 ranking in the Scopus category of Hematology, placing it in the top 18% of the field. The journal encompasses a broad range of topics including clinical and laboratory aspects of blood disorders and hematological malignancies, making it an essential resource for hematologists, researchers, and healthcare professionals. With its commitment to publishing top-tier research and clinical studies, the British Journal of Haematology plays a critical role in shaping treatment approaches and improving patient outcomes worldwide. Please note that this journal does not offer Open Access options, ensuring that published content is rigorously curated for quality and relevance.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Championing research excellence in blood disorders and cancers.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1077-4114Frequency: 8 issues/year

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, published by Lippincott Williams & Wilkins, serves as a vital platform for the dissemination of cutting-edge research and insights in the fields of pediatric hematology and oncology. Since its inception in 1979, the journal has maintained a commitment to advancing knowledge through peer-reviewed articles that contribute to the understanding and treatment of blood disorders and cancers in children. With an impact factor reflective of its academic contributions, the journal is positioned in the Q3 quartile across key medical categories — Hematology, Oncology, and Pediatrics, Perinatology and Child Health — indicating its relevance and influence in the field. While it does not currently offer open access options, the journal remains a crucial resource for researchers, clinicians, and students dedicated to improving pediatric care and outcomes. Researchers are encouraged to contribute to this esteemed journal as it seeks to bridge the gap between clinical practice and research, fostering innovation and improved quality of life for young patients affected by hematologic and oncologic conditions.

LEUKEMIA RESEARCH

Elevating the standards of leukemia research and care.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0145-2126Frequency: 12 issues/year

Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.

CANCER JOURNAL

Exploring New Frontiers in Cancer Mechanisms and Therapies.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1528-9117Frequency: 6 issues/year

CANCER JOURNAL is a leading peer-reviewed publication dedicated to the dissemination of innovative research in the fields of cancer research and oncology. Published by Lippincott Williams & Wilkins, this journal serves as an essential resource for researchers, clinicians, and students seeking to advance their understanding of cancer mechanisms, treatment strategies, and patient care. With an ISSN of 1528-9117 and an E-ISSN of 1540-336X, it boasts a respectable 2023 Q2 category ranking in both Cancer Research and Oncology, reflecting its impactful contributions to the scientific community. Although it currently does not offer open access, the journal's rigorous peer-review process ensures the publication of high-quality, relevant studies that stimulate further investigation and collaboration among professionals. Since its inception, the journal has evolved through several converged years, maintaining a steadfast commitment to addressing the complexities of cancer biology and treatment. At its core, CANCER JOURNAL aims to foster advancements in oncology, making it a vital platform for sharing pivotal findings that could transform cancer research and therapeutic practices.